VENLO, Netherlands / Jul 08, 2025 / Business Wire / QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025.
Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2480
Conference ID: 1992038
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link: https://event.webcasts.com/viewer/event.jsp?ei=1709551&tp_key=978ad5a0e6
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and costeffective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
| Last Trade: | US$46.85 |
| Daily Change: | 0.52 1.12 |
| Daily Volume: | 1,236,259 |
| Market Cap: | US$10.160B |
September 10, 2025 September 02, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load